Allulose Stimulates GLP-1 — The Same Hormone Targeted by Ozempic

Allulose Triggers Your Body's Own GLP-1 — Independently of Sweetness

This is the most scientifically important finding about allulose, and it's published in Nature Communications (2018) — one of the world's top scientific journals. The finding: allulose stimulates the release of GLP-1 (glucagon-like peptide-1), one of the body's master metabolic hormones.

GLP-1 is the same hormone that the blockbuster weight-loss drugs semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are designed to mimic. Those drugs are synthetic GLP-1 receptor agonists — they flood the body with a lab-made version that lasts for days. Allulose, by contrast, nudges your own intestinal cells to release your body's natural GLP-1 at mealtime.

The effect is much more modest than a drug — but it comes from a food ingredient with no side effects.

The Experiment That Proved Causality

A research team led by Yusaku Iwasaki at Kyoto University conducted a series of rigorous experiments. Here's what they found, step by step:

Experiment 1: Does allulose actually increase GLP-1? Yes. Oral allulose potently increased active GLP-1 levels in the blood within 15-30 minutes of ingestion. Importantly, allulose triggered GLP-1 specifically — it did not affect GIP, CCK, or PYY (other gut hormones).

Experiment 2: Where does the GLP-1 come from? The intestinal L-cells in the small intestine. Allulose reaches these cells after ingestion and directly stimulates them to release GLP-1.

Experiment 3: Does it go through the sweet taste receptor? No — and this is crucial. Allulose does NOT activate T1R2/T1R3 sweet taste receptors. The GLP-1 release is independent of sweetness signaling. This means:

• Artificial sweeteners (sucralose, aspartame) that activate sweet receptors do NOT trigger GLP-1 through this pathway
• Allulose works through a different, currently unidentified receptor on L-cells
• The body treats allulose as a metabolic signal, not as a "sweet thing"

Experiment 4: What happens if we block GLP-1 receptors? When the researchers used GLP-1 receptor knockout mice, ALL of allulose's metabolic benefits completely disappeared: no improvement in glucose tolerance, no reduction in food intake, no body weight effect. This is the smoking gun — GLP-1 is not just correlated with the benefits; it is the causal mechanism.

Experiment 5: What happens if we cut the vagus nerve? The vagus nerve is the main communication line between the gut and the brain. After surgical vagotomy, allulose's effects vanished. This confirms the pathway: allulose → gut L-cells → GLP-1 → vagus nerve → brain.

Experiment 6: Does the GLP-1 actually reduce eating? Yes. The vagal signal reaches the nucleus tractus solitarius in the brainstem (the brain's "gut information processing center"), which then signals satiety. Allulose-treated animals ate less — and this was GLP-1 dependent.

Human Confirmation — Two Trials, Consistent Results

Teysseire et al. (2022) — Randomized crossover trial in healthy adults

A Swiss research team at the University of Basel conducted a rigorous within-subject crossover trial. Participants received 10g allulose vs. water (control), with GLP-1, CCK, and PYY measured at multiple time points. 10g allulose significantly increased circulating GLP-1, CCK, and PYY levels — confirming that the gut hormone response observed in rodent models translates directly to humans. Notably, the GLP-1 response was rapid (within 15-30 minutes), matching the time course seen in the Iwasaki animal experiments.

Iba et al. (2026) — bioRxiv preprint: GLP-1 effect in a postmenopausal model

A 2026 preprint extended the GLP-1 findings to a postmenopausal animal model — a population that faces elevated metabolic risk due to estrogen decline. Allulose stimulated GLP-1 secretion and improved metabolic parameters in this model, suggesting the GLP-1 mechanism remains functional even under the metabolic stress of estrogen loss. While this is a preprint (not yet peer-reviewed), it extends the evidence base to a clinically important population.

Together, these studies tell us: the GLP-1 mechanism works in humans, not just in animal models, and it may be particularly relevant for populations with elevated metabolic risk.

Why This Matters — Plain Language

Here's the practical significance:

• GLP-1 is your body's "I'm full" signal. It tells your pancreas to release insulin, your liver to stop making glucose, and your brain to stop eating. By boosting natural GLP-1 at mealtime, allulose helps your body's own satiety system work better.

• This is fundamentally different from other sweeteners. Erythritol, stevia, sucralose, aspartame — none of them stimulate GLP-1 through this pathway. They are "metabolically inert." Allulose is "metabolically active" — it participates in your body's regulatory systems in a beneficial way.

• This is why allulose is sometimes called a "functional sweetener." It doesn't just replace sugar — it adds a metabolic health benefit that sugar doesn't have.

Allulose vs. GLP-1 Drugs — Honest Comparison

	Allulose 5-10g	Semaglutide (Wegovy 2.4mg)
How it works	Stimulates your own L-cells to release natural GLP-1	Synthetic GLP-1 analog that lasts ~7 days in blood
GLP-1 increase	Modest, meal-time pulse	Pharmacological, continuously elevated
Weight loss	Modest (see Fat Metabolism)	~15% body weight in clinical trials
Side effects	None at normal doses	Nausea, vomiting, diarrhea (common); rare but serious thyroid, pancreatic risks
Cost	Food ingredient cost (~$0.10-0.30/day)	~$1,000+/month (US list price)
Regulatory status	Food ingredient (GRAS)	Prescription drug
Role	Dietary tool for metabolic health support	Medical treatment for obesity and type 2 diabetes

Allulose is not a replacement for GLP-1 medications — they serve different purposes. But for someone looking to support metabolic health through diet, allulose offers a scientifically validated, low-cost, zero-side-effect way to engage the body's own GLP-1 system at every meal.

Bottom Line

The GLP-1 finding is what separates allulose from every other low-calorie sweetener on the market. The mechanism is causal (proven by knockout experiments), the pathway is mapped (L-cell → GLP-1 → vagus → brain), and the human relevance is confirmed. No other sweetener has this evidence profile.

Sources: Iwasaki Y, Sendo M, Dezaki K, et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nature Communications. 2018;9:113. doi:10.1038/s41467-017-02488-y; Teysseire F, et al. Allulose affects energy intake, GLP-1, CCK, and PYY in healthy adults: a randomized controlled crossover trial. 2022; Iba Y, et al. D-Allulose improves metabolic parameters via GLP-1 in a postmenopausal model. bioRxiv. 2026.